# Dose Escalation of HSP990 in Japan/Korea

> **NCT01064089** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** HSP990

## Key facts

- **NCT ID:** NCT01064089
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064089, "Dose Escalation of HSP990 in Japan/Korea". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01064089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*